187 related articles for article (PubMed ID: 33446713)
1. A study of the dopamine transporter using the TRACT assay, a novel in vitro tool for solute carrier drug discovery.
Sijben HJ; van den Berg JJE; Broekhuis JD; IJzerman AP; Heitman LH
Sci Rep; 2021 Jan; 11(1):1312. PubMed ID: 33446713
[TBL] [Abstract][Full Text] [Related]
2. Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1.
Vlachodimou A; IJzerman AP; Heitman LH
Sci Rep; 2019 Sep; 9(1):13802. PubMed ID: 31551431
[TBL] [Abstract][Full Text] [Related]
3. Advantages and shortcomings of cell-based electrical impedance measurements as a GPCR drug discovery tool.
Doijen J; Van Loy T; Landuyt B; Luyten W; Schols D; Schoofs L
Biosens Bioelectron; 2019 Jul; 137():33-44. PubMed ID: 31077988
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a novel microscale thermophoresis ligand-binding assay for characterization of SLC solute carriers using oligopeptide transporter PepT1 (SLC15 family) as a model system.
Clémençon B; Lüscher BP; Hediger MA
J Pharmacol Toxicol Methods; 2018; 92():67-76. PubMed ID: 29580877
[TBL] [Abstract][Full Text] [Related]
5. Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter.
Ukairo OT; Ramanujapuram S; Surratt CK
Brain Res; 2007 Feb; 1131(1):68-76. PubMed ID: 17169338
[TBL] [Abstract][Full Text] [Related]
6. Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells.
Chen N; Reith ME
J Neurochem; 2007 Apr; 101(2):377-88. PubMed ID: 17250655
[TBL] [Abstract][Full Text] [Related]
7. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs.
Marazziti D; Mandillo S; Di Pietro C; Golini E; Matteoni R; Tocchini-Valentini GP
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9846-51. PubMed ID: 17519329
[TBL] [Abstract][Full Text] [Related]
8. Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors.
Sijben HJ; van Oostveen WM; Hartog PBR; Stucchi L; Rossignoli A; Maresca G; Scarabottolo L; IJzerman AP; Heitman LH
Sci Rep; 2021 Jun; 11(1):12290. PubMed ID: 34112854
[TBL] [Abstract][Full Text] [Related]
9. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.
Chen N; Zhen J; Reith ME
J Neurochem; 2004 May; 89(4):853-64. PubMed ID: 15140185
[TBL] [Abstract][Full Text] [Related]
10. A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain.
Xie Z; Miller GM
J Pharmacol Exp Ther; 2009 Jul; 330(1):316-25. PubMed ID: 19364908
[TBL] [Abstract][Full Text] [Related]
11. Differential influence of dopamine transport rate on the potencies of cocaine, amphetamine, and methylphenidate.
Calipari ES; Ferris MJ; Siciliano CA; Jones SR
ACS Chem Neurosci; 2015 Jan; 6(1):155-62. PubMed ID: 25474655
[TBL] [Abstract][Full Text] [Related]
12. Nongenomic mechanisms of physiological estrogen-mediated dopamine efflux.
Alyea RA; Watson CS
BMC Neurosci; 2009 Jun; 10():59. PubMed ID: 19531209
[TBL] [Abstract][Full Text] [Related]
13. Behavior of knock-in mice with a cocaine-insensitive dopamine transporter after virogenetic restoration of cocaine sensitivity in the striatum.
O'Neill B; Tilley MR; Han DD; Thirtamara-Rajamani K; Hill ER; Bishop GA; Zhou FM; During MJ; Gu HH
Neuropharmacology; 2014 Apr; 79():626-33. PubMed ID: 24412674
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Assays for the Functional Characterization of the Dopamine Transporter (DAT).
Aggarwal S; Mortensen OV
Curr Protoc Pharmacol; 2017 Dec; 79():12.17.1-12.17.21. PubMed ID: 29261226
[TBL] [Abstract][Full Text] [Related]
15. The dopamine transporter expression level differentially affects responses to cocaine and amphetamine.
Cagniard B; Sotnikova TD; Gainetdinov RR; Zhuang X
J Neurogenet; 2014; 28(1-2):112-21. PubMed ID: 24673634
[TBL] [Abstract][Full Text] [Related]
16. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.
Wang W; Sonders MS; Ukairo OT; Scott H; Kloetzel MK; Surratt CK
Mol Pharmacol; 2003 Aug; 64(2):430-9. PubMed ID: 12869648
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation.
Gorentla BK; Vaughan RA
Neuropharmacology; 2005 Nov; 49(6):759-68. PubMed ID: 16181646
[TBL] [Abstract][Full Text] [Related]
19. Comparing label-free biosensors for pharmacological screening with cell-based functional assays.
Peters MF; Vaillancourt F; Heroux M; Valiquette M; Scott CW
Assay Drug Dev Technol; 2010 Apr; 8(2):219-27. PubMed ID: 20085460
[TBL] [Abstract][Full Text] [Related]
20. Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs.
Eriksen J; Rasmussen SG; Rasmussen TN; Vaegter CB; Cha JH; Zou MF; Newman AH; Gether U
J Neurosci; 2009 May; 29(21):6794-808. PubMed ID: 19474307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
